Overview

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

Status:
Terminated

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression

Phase:

Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Rituximab